Table 2.

Overall efficacy and cellular kinetics (infused patients, N = 9)

Efficacy and cellular kinetic variables	Patient A	Patient B	Patient C	Patient D	Patient E	Patient F	Patient G	Patient H	Patient I
Best overall response	CR	PD	CR	PR	PR	CR	CR	PD	CR
Time to response, days	28	–	28	31	28	30	90	–	91
Duration of response, days	523+	–	51+	55	52+	148+	1+	–	1+
Progression-free survival, days	550+	29	78+	85	79+	177+	90+	36	91+
Event-free survival, days	550+	29	78+	85	126	207	90+	36	91+
Overall survival, days	710+	231	144+	86+	183+	207+	160+	45	91+
AUC0–28d, copies/µg × days	83,800	35,400	21,700	34,200	57,600	7290	189,000	1,740,000	2730
Cmax, copies/µg	9410	6120	2470	4420	5840	846	11,900	137,000	149
Tmax, days	5.82	5.85	8.78	12.9	5.73	6.96	11.0	26.7	19.8
T1/2, days	408	7.53	26.6	1.18	32.4	4.16	77.9	2.72	-

AUC_0-28d area under the concentration–time curve from time 0 to day 28, C_max maximum concentration, CR complete response, PD progressive disease, PR partial response, T_1/2 half-life, T_max time to maximum expansion, + flags censored observations